Active — Not RecruitingNot Applicable

The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria

Greece60 participantsStarted 2018-02-01

Plain-language summary

Patients with Type 2 Diabetes Mellitus and albuminuria will be randomised eitheer to dulaglutide and dapagliflozin combination or DPP-4 inhibitor, as an add-on treatment to metformin. Arterial stiffness, UACR, endothelial glycocalyx and global longitudinal strain will be assesed at baseline, 4 and 12 months.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Type 2 diabetes mellitus Albuminuria HbA1c: 7-10% eGFR\> 60 ml/min Exclusion Criteria: * Type 1 diabetes mellitus Inflammation, chronic or acute Established cardiovascular disease Malignancy within the last 5 years

What they're measuring

UACR

Timeframe: 4 and 12 months

PWV

Timeframe: 4 and 12 months

PBR

Timeframe: 4 and 12 months

GLS

Timeframe: 4 and 12 months

Trial details

NCT IDNCT06611904

SponsorAttikon Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-02-05

View on ClinicalTrials.gov More Urine Albumin (UAlb) trials